2023 World Conference on Lung Cancer (Posters)-EP13.05. Effects and Outcomes Analysis of Immunotherapy for Patients with Pulmonary Large-Cell Neuroendocrine Carcinoma

EP13.05. Effects and Outcomes Analysis of Immunotherapy for Patients with Pulmonary Large-Cell Neuroendocrine Carcinoma - PDF(Abstract)

Back to course

Pdf Summary

This study analyzed the effects and outcomes of immunotherapy for patients with pulmonary large-cell neuroendocrine carcinoma (LCNEC), a rare lung malignancy with limited information on the efficacy of immune checkpoint inhibitors. The researchers retrospectively studied patients treated in Shanghai Chest Hospital from 2017 to 2021 who received either chemotherapy alone or immunotherapy combined with chemotherapy in the first line. They assessed objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) of the two groups and investigated the correlation between serum tumor markers and PFS.<br /><br />The study included a total of 45 LCNEC patients. The results showed that the ORR, DCR, and PFS were comparable between the immunotherapy combined with chemotherapy group and the chemotherapy alone group. For the programmed cell death ligand-1 (PD-L1) negative population, chemotherapy alone had a significantly longer PFS compared to immunotherapy combined with chemotherapy. However, for PD-L1 positive or not available patients, PFS was better with immunotherapy combined with chemotherapy. Furthermore, the baseline blood cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) levels greater than 3.5ng/ul in the immunotherapy combined with chemotherapy group were independently associated with shorter PFS.<br /><br />In conclusion, this study found that immunotherapy combined with chemotherapy does not provide a benefit for PD-L1-negative patients with advanced LCNEC, who have a significantly longer PFS with chemotherapy alone. However, PD-L1-positive patients may have a longer PFS with immunotherapy combined with chemotherapy. Additionally, the baseline serum CYFRA21-1 value may serve as an independent prognostic factor for PFS in LCNEC.

Asset Subtitle

Tianqing Chu

Meta Tag

Speaker Tianqing Chu

Topic SCLC & Neuroendocrine Tumors: NETs

Keywords

immunotherapy

pulmonary large-cell neuroendocrine carcinoma

LCNEC

immune checkpoint inhibitors

chemotherapy

objective response rate

disease control rate

progression-free survival

overall survival

serum tumor markers